Revascularization in severe left ventricular dysfunction: the role of viability testing.
Revascularization is a treatment option for moderate-to-severe ischemic cardiomyopathy. Limitations of the current literature, lack of completed randomized trials, and higher periprocedural risks create significant uncertainty about the optimal treatment strategy. This review focuses on the available literature describing the effect of revascularization on outcome and the role of noninvasive viability testing. It attempts to identify a subset of patients likely to benefit from therapy.
Chareonthaitawee
Panithaya
P
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA. chareonthaitawee.panithaya@mayo.edu
Gersh
Bernard J
BJ
Araoz
Philip A
PA
Gibbons
Raymond J
RJ
D000465:Algorithms; D009202:Cardiomyopathies / Q000175:diagnosis / Q000601:surgery; D003952:Diagnostic Imaging / Q000379:methods; D006801:Humans; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000601:surgery; D009204:Myocardial Revascularization; D012306:Risk; D014022:Tissue Survival; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis* / Q000503:physiopathology / Q000601:surgery*